Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study aimed at identifying novel molecular cancer drug targets and biomarkers by analyzing the gene expression profiles of high-grade
prostate cancer
(PC), using a cDNA microarray combined with laser microbeam microdissection. A number of genes were identified that were transactivated in high-grade PC. First, a novel molecular target and diagnostic biomarker, shisa family member 2 (
SHISA2
), was identified as an overexpressed gene in high-grade PC cells. The reverse transcription-semi-quantitative polymerase chain reaction and immunohistochemical analysis validated the overexpression of
SHISA2
(295 amino acids in length), specifically in high-grade PC cells with Gleason scores of between 8 and 10, relative to normal prostate epithelium. Knockdown of
SHISA2
expression by short interfering RNA resulted in the marked suppression of PC cell viability. By contrast, exogenous
SHISA2
expression in transfected cells promoted PC cell proliferation, indicating its oncogenic effects. Notably, as a result of cDNA microarray analysis, protein Wnt-5a (WNT5A) was focused upon and the expression of WNT5A was identified to be downregulated in
SHISA2
-knockdown. Western blot analysis validated significant downregulation of WNT5A by
SHISA2
-knockdown and upregulation of WNT5A by
SHISA2
overexpression. The results of the present study indicated that
SHISA2
may affect WNT5A synthesis. Furthermore, the secreted
SHISA2
protein was determined in the culture medium of PC cells. We hypothesize that
SHISA2
is involved in the regulation of WNT5A and in the aggressiveness of PC via the Wnt signaling pathway through WNT5A. Furthermore,
SHISA2
may be a molecular target for cancer drugs, and a useful diagnostic biomarker for the prognosis and therapeutic effect in cancer.
...
PMID:SHISA2 enhances the aggressive phenotype in prostate cancer through the regulation of WNT5A expression. 2934 18